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ORIGINAL STUDY
Two Cases of Primary Cutaneous Lymphoma With a
g/d+ Phenotype and an Indolent Course: Further Evidence
of Heterogeneity of Cutaneous g/d+ T-Cell Lymphomas
Werner Kempf, MD,* Dmitry V. Kazakov, MD, PhD,† Paul E. Scheidegger, MD,‡
Max Schlaak, MD,§ and Iliana Tantcheva-Poor, MD§
Abstract: Cutaneous g/d+ T-cell lymphoma (CGD-TCL) is a rare
but aggressive lymphoma associated with a poor prognosis in most
patients. The clinicopathological spectrum is variable including pre-
dominantly epidermotropic inﬁltrates manifesting with patches and
plaques or tumors with dermal and/or subcutaneous inﬁltrates. The
diagnosis of CGD-TCL requires the demonstration of a g/d+ pheno-
type by immunohistochemistry. We report 2 patients with epidermo-
tropic cutaneous T-cell lymphomas displaying a g/d+ phenotype, but
exhibiting an indolent course. In one patient, the clinical presentation
was similar to mycosis fungoides in patch and plaque stage, but recur-
rent blister formation within the lesions was observed accompanied by
fever and arthralgias, whereas the second patient presented with 2
localized erosive plaques on the left temple and dense epidermotropic
and dermal diffuse and folliculotropic inﬁltrates of atypical small-to-
medium–sized lymphocytes. These cases corroborate the view that
expression of a g/d+ phenotype in cutaneous T-cell lymphomas per
se does not portend a worse prognosis and that CGD-TCL may rep-
resent a clinically and prognostically heterogeneous group.
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INTRODUCTION
The g/d T cells are a minor subset (,5%) of peripheral
blood lymphocytes, representing an essential part of innate
immune system and playing an important role in immunosur-
veillance.1 By deﬁnition, they express the g/d T-cell receptor
(TCR) and cytotoxic molecules. When activated, g/d T cells
can additionally express one or more natural killer–associated
surface molecules (CD56, CD16, CD57), morphologically
appearing in the activated stage as large and granular cells.
The g/d+ T cells are only exceptionally encountered in cuta-
neous inﬂammatory lymphocytic inﬁltrates, and usually their
number does not exceed 5%–10% of the entire inﬁltrate.2 Their
malignant counterparts are thought to derive from local pop-
ulations residing in some epithelial tissues, mirroring distribu-
tion of g/d+ T-cell lymphomas, namely the skin and intestine.
Cutaneous g/d+ T-cell lymphoma (CGD-TCL) is a rare
and usually aggressive disease with a poor prognosis.3–5 It is
listed as a provisional entity in the World Health Organization
(WHO)–European Organization for Research and Treatment
of Cancer (EORTC) classiﬁcation and represents a distinct
lymphoma entity in the WHO classiﬁcation (fourth edition,
2008).4,6 Histologically, CGD-TCL presents with epidermo-
tropic, dermal and/or subcutaneous inﬁltrates, or combinations
of these patterns even in the same individual. In the past, the
lack of a/b TCR expression (beta F1) by neoplastic lympho-
cytes was uniformly accepted as a criterion for assigning a g/d
TCR phenotype, but recently, a new commercially available
antibody recognizing the TCRg subunit of the TCR in forma-
lin-ﬁxed and parafﬁn-embedded tissue was introduced.7 Using
this antibody, 2 groups have recently conducted studies on
a large series of cutaneous T-cell lymphoma (CTCL) and con-
cluded that the expression TCRg is not exclusive to CGD-TCL
because TCRg was also identiﬁed in rare cases of other CTCL
such as mycosis fungoides (MF) and lymphomatoid papulosis
(LyP).8,9 We present 2 cases of primary CTCL with expression
of TCRg, but an indolent course supporting the suggestion that
CTCL with a g/d+ phenotype may represent a prognostically
heterogeneous group and may clinically and histologically
overlap with MF.8,10
CASE 1
Clinical Features
A 64-year-old man presented with asymptomatic, generalized,
symmetrical, partly conﬂuent patches and indurated plaques involving
the trunk, upper and lower extremities, inguinal areas, and anterior
neck that had been present for about a year. Some of the red-brown
lesions were scaly, whereas others were circinate (Figs. 1A–C). No
symptoms were reported, but the patient stated that he had been expe-
riencing episodes of high fever (up to 38–398C), arthralgia (hands and
wrists), and vesicles and blisters (Fig. 1D) occurring approximately
once per month and lasting for 2–3 days during the previous year.
Blisters always healed leaving no scars. The clinical diagnosis was
bullous lupus erythematosus or erythema gyratum repens. All labora-
tory results including peripheral blood lymphocyte count, viral serol-
ogy (herpes simplex virus 1/herpes simplex virus 2, HIV, and human
herpesvirus 8), and hepatitis serology (Hepatitis B surface antigen,
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anti–hepatitis C virus antibodies) were normal/negative. The patient’s
family history was signiﬁcant for multiple malignant tumors including
pulmonary carcinoma (father), Hodgkin disease (older brother), and
brain tumor (youngest brother).
After histological diagnosis of epidermotropic cutaneous
lymphoma, the patient underwent staging investigations including
bone marrow biopsy and positron emission tomography/computed
tomography, but no extracutaneous disease was found. Methotrexate
in combination with psoralen-UV-A was administered but resulted in
no improvement, though episodes of fever and blisters become less
frequent. Acitretin 2 · 10 mg was then tried but that was also
ineffective. Prednisone (ﬁrst 50 mg, later 15 mg/d) was administered
in combination with topical steroids (betametasone-17-valerate)
cream. Most skin lesions (above 75%) regressed, and the patient is
alive with few patches on the extremities, 19 months after diagnosis
(Fig. 2).
Histopathological, Immunohistochemical,
and Molecular Biologic Data
Four biopsies taken within a year and one specimen for direct
immunoﬂuorescence (DIF) studies were available for review. All
4 biopsies showed similar features (only density of the inﬁltrate
varied), including scale, crusts, spongiosis, and an inﬁltrate com-
posed of small lymphocytes with only slightly convoluted nuclei
inﬁltrating the epidermis, focally lining up in the basal layer. Rare
intraepidermal lymphocytes were larger than their dermal counter-
parts (Figs. 3A, B). Occasional neutrophils, eosinophils, and macro-
phages were present, the latter in foci with subtle vacuolar alteration
at the dermoepidermal junction. One of the 4 biopsies showed sub-
epidermal and subsequent intraepidermal blisters and an admixture
of eosinophils in addition to the above-described epidermotropic
inﬁltrates but no apoptotic keratinocytes in the detached epidermis
(Fig. 3C).
Immunohistochemically, the inﬁltrate consisted exclusively of
T cells expressing CD3 (80%–90%), CD4 (50%), and TCRg (80%)
(Fig. 4). Only occasional cells expressed CD2, CD7, and beta F1. No
expression was seen with CD56 and CD57. T-cell intracellular anti-
gen-1 was expressed by almost all g/d+ lymphocytic tumor cells,
whereas granzyme B was absent. There were slight differences
regarding expression of CD30 and PD-1 between the initial biopsy
and the one taken 10 months later. Whereas in the initial specimen,
approximately 20% of small lymphocytes (especially intraepidermal
ones) expressed CD30 and PD-1, the number of CD30 and PD-1–
positive cells amounted to 70%–80% in the subsequent biopsies
including the one with blister formation.
DIF of the biopsy with blister formation revealed no deposits
of immunoglobulin IgA, IgG, IgM, C3, or ﬁbrinogen along the
junctional zone or within the epidermis. Furthermore, indirect
immunoﬂuorescence and salt-split skin examination did not show
antibodies against basement membrane components or epidermal
antigens.
Molecular biologic studies using BIOMED 2 primers revealed
monoclonal rearrangements of TCRg genes.11 Epstein-Barr virus–
encoded small RNA (EBER) in situ hybridization was negative.
DIF examination revealed no abnormal deposits, arguing
against a bullous disorder or lupus erythematosus.
CASE 2
Clinical Features
An 82-year-old man presented with 2 rapidly growing lesions
situated between the lateral canthus and the ear. Both lesions, one
small and one large, were slightly elevated and crusted with an
erythematous rim. A scar was evident above the larger lesion (Fig. 5A).
No signiﬁcant medical or family history was known.
After histological diagnosis, the patient underwent clinical
investigation (except for bone marrow biopsy); no extracutaneous
disease was identiﬁed. The patient was treated by local radiotherapy
2 · 4 Gy that resulted in complete remission (Fig. 5B). The patient is
alive with no evidence of disease 11 months after diagnosis.
Histopathological, Immunohistochemical,
and Molecular Biologic Data
The epidermis was focally ulcerated, but otherwise largely
atrophic with loss of rete ridges. The dermis contained a dense
diffuse inﬁltrate composed of small-to-medium–sized lymphocytes
with irregular hyperchromatic nuclei. The cells displayed marked
epidermotropism lining up on the basal layer of the epidermis and
FIGURE 1. Case 1. A and B, Widespread symmetrical patches involving the trunk and extremities. C, Close-up of some lesions.
D, Blister formation within a plaque on left upper arm.
FIGURE 2. Case 1. Posttreatment clinical appearance with
regression of the lesions.
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also forming a small collection in the spinous layer (Pautrier micro-
abscesses). In addition, there was marked folliculotropism, with vir-
tually all vellus hair follicles present in the specimen being diffusely
inﬁltrated by the lymphoid cells (Fig. 6).
Immunohistochemically, the inﬁltrate consisted exclusively of
T cells expressing CD3 (100%) and TCRg (70%) (Fig. 7). Other
T-cell markers were expressed as follows: CD2 (10%), CD4 (20%),
CD56 (weak, 10%), beta F1 (10%), and PD-1 (10%) (Fig. 7). Cyto-
toxic markers could not be examined because of the lack of sufﬁcient
tissue. Negative immunoreactivity was seen with CD7, CD20, and
CD30. The proliferation index (MIB-1) of atypical cells was 70%.
Monoclonal rearrangements of TCRg genes were detected
using BIOMED 2 protocol.11 EBV in situ hybridization (EBER)
was negative.
DISCUSSION
We report 2 patients with epidermotropic lymphoid
inﬁltrates in which the neoplastic cells expressed TCRg as
demonstrated by immunohistochemistry on formalin-ﬁxed
and parafﬁn-embedded tissue. Based on this ﬁnding, the diag-
nosis of CGD-TCL has to be seriously considered, particularly
because CGD-TCL may histologically present with predomi-
nantly epidermotropic inﬁltrates.6 CGD-TCL is generally
regarded as an aggressive lymphoma with a poor prognosis.
In our patients, however, the disease did not follow the
expected aggressive course. In both the patients, the lymphoma
was controlled by radiotherapy or steroids. In regard to this
unusual indolent course and the clinical presentation in patient
1, MF with a g/d+ phenotype has to be considered as a differ-
ential diagnosis, especially because other CTCL recently have
been found to express this phenotype rarely.8,9 Only a few
cases diagnosed as MF or MF-like lymphoma with a g/d+
phenotype have been reported.12–14 Guitart et al8 in their series
of 53 cases of CTCL with g/d+ phenotype identiﬁed obviously
6 such patients to whom they referred as “MF-like” CGD-
TCL; the disease in these patients followed a more indolent
course. In contrast, some experts classiﬁed similar cases of
epidermotropic inﬁltrates of TCRg+ cells based on the clinical
presentation with patches and plaques straightforward as MF,
labeling them as “TCRg+ MF.”9 In our patient, the patches and
plaques were clinically typical for MF. The episodes of high
fever and blisters are very unusual although blister formation
FIGURE 3. Case 1. A and B, Epidermotropic infiltrate composed of small lymphocytes showing striking epidermotropism with
lining up in the basal layer of the epidermis. C, Subepidermal and intraepidermal blister formation.
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has been documented in a patient with MF (so-called MF
bullosa), whereas fever and symptoms of rheumatic diseases
are not uncommonly observed in CGD-TCL.15,16 The reason
for recurrent blister formation is unknown. It can be speculated
that cytokines released in a cyclic manner result in blister
formation, fever, and arthralgias. Notably, the neoplastic cells
in this case also expressed CD30, thus making LyP type D
a histological differential diagnostic consideration.17 However,
FIGURE 4. Case 1. Immunohistochemical staining for TCRg (A); beta F1 (B); CD2 (C, note loss of CD2); CD3 (D); CD30 (E); and
PD-1 (F).
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FIGURE 5. Case 2. The clinical appearance of the
lesions before (A) and after (B) treatment.
FIGURE 6. Case 2. A dense infiltrate in the dermis (A) with marked epidermotropism (B) and folliculotropism (C). The infiltrate is
composed of small lymphocytes with hyperchromatic nuclei and halo (D).
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LyP type D, as with other LyP types, is characterized by pap-
ulonodular lesions with a typical waxing and waning course
and spontaneous regression, whereas in our patients, no such
clinical presentation was seen.18–21 Our second case showed
some features suggestive of folliculotropic MF. The absence
of the subcutis in the biopsy specimen is a diagnostic limitation
because CGD-TCL more often involves the subcutis than does
folliculotropic MF. From the clinical standpoint, erosions are
typical features of CGD-TCL. However, the good response to
therapy with complete remission lasting 9 months would be
unusual for CGD-TCL and would favor the diagnosis of MF.
Based on the clinical presentation and the expression of TCRg,
however, this case may represent an unusual indolent epider-
motropic and folliculotropic form of CGD-TCL.
The constellation in the presented cases exempliﬁes a
diagnostic dilemma in CTCL. Expression of a g/d+ phenotype
is an essential diagnostic criterion for CGD-TCL, but other
forms of CTCL with their classic clinical presentation rarely
can display g/d+ phenotype. Because of overlapping histolog-
ical features with other CTCL, delineation from authentic
FIGURE 7. Case 2. Immunohistochemical staining for TCRg (A), beta F1 (B), CD2 (C), and CD3 (D).
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CGD-TCL on histopathological grounds alone is difﬁcult and
perhaps remains often arbitrary. Such cases raise the question,
whether the demonstration of a g/d+ phenotype can be used as
a necessary and sufﬁcient criterion to classify the lymphomas
as CGD-TCL with an unusually indolent course or whether the
indolent course should be used as a decisive argument to clas-
sify them as MF with a g/d+ phenotype. The answer to this
dilemma has not only an impact on the terminology and clas-
siﬁcation but also more importantly on the therapeutic
approach. Because CGD-TCL is considered as an aggressive
lymphoma with a poor prognosis, the diagnosis of this lym-
phoma usually implies the need for an aggressive therapeutic
approach with multiagent chemotherapy, eventually in combi-
nation with alemtuzumab and followed by stem cell transplan-
tation.22 In contrast, phototherapy (psoralen-UV-A or UV-B
narrowband) combined with topical corticosteroids or retinoids
are the ﬁrst-line strategy for MF in patch/plaque stage.23,24 The
situation becomes even more complex by the increasing insight
into the wide prognostic spectrum even within the individual
CTCL entities. For example, extranodal natural killer/T-cell
lymphoma, nasal type, usually shows an aggressive course
similar to CGD-TCL. However, cases with a chronic indolent
course have recently been reported, challenging the concept
that this lymphoma shows always an aggressive course and
poor prognosis.25 In analogy, one could argue that our cases
represent an epidermotropic and folliculotropic subtype of
CGD-TCL characterized by an indolent course and not requir-
ing aggressive therapy. Recently, a case of a 57-year-old
woman with a 3-year history of an indolent CGD-TCL was
reported by Endly et al.10 This CGD-TCL presented with nod-
ules on the leg and predominantly subcutaneous g/d clonal
T-cell inﬁltrates that rapidly improved within months of start-
ing systemic corticosteroids.10 Response of CGD-TCL with
epidermotropic, dermal, and subcutaneous inﬁltrates to radio-
therapy, retinoid, and UV-B narrowband was observed in
a 62-year-old woman.26 No matter what name is attached to
similar cases, it will be important to identify prognostic and
therapeutic markers for these rare CTCL.
A high number of PD-1–positive lymphocytes were
found in case 1. The latter marker labels follicular helper
T cells, which are normally present in germinal centers and
possess helper function for B cells.27 It also stains activated
T cells and has been found in different forms of CTCL includ-
ing MF and Sézary syndrome at variable degree range from 9%
to 80% of cases harboring PD-1–positive T cells.28,29 PD-1 is
of interest because it may serve as a therapeutic marker.30
In conclusion, these 2 cases conﬁrm the previous
observation that a g/d phenotype in CTCL per se does not
confer a worse prognosis in all cases. More studies and
observations are warranted to shed light on the correct clas-
siﬁcations of such cases to establish whether they represent
a variant of MF or a more indolent form of epidermotropic
or folliculotropic CGD-TCL for which less aggressive treat-
ment may be effective.10,26,31,32
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